Isoniazid Morningside Healthcare

Isoniazid, the active ingredient in Isoniazid Morningside Healthcare, is an antitubercular agent presented as an oral tablet for oral use. It is employed in the treatment and prevention of tuberculosis in adults and children when prescribed by a qualified health professional.

GNH USA supplies Isoniazid Morningside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoniazid is an antitubercular drug used to manage infections caused by Mycobacterium tuberculosis. - Active tuberculosis: contributes to bacterial kill and shortens treatment duration when combined with other anti‑TB agents. - Latent tuberculosis infection: provides prophylaxis to prevent progression to active disease. - Post‑exposure prophylaxis: given to close contacts of confirmed cases to reduce infection risk.

Isoniazid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Mild peripheral neuropathy (tingling or numbness) - Elevated liver enzymes - Rash or mild skin irritation - Fever or flu‑like symptoms

Serious or Rare Side Effects: - Hepatotoxicity (jaundice, severe liver injury) - Severe peripheral neuropathy - Allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Hemolytic anemia in patients with G6PD deficiency - Drug‑induced lupus‑like syndrome - Acute interstitial nephritis

Before initiating therapy, clinicians should evaluate patient history and laboratory parameters. - Liver function monitoring: obtain baseline transaminases and repeat periodically, especially in patients with pre‑existing liver disease. - Neuropathy prevention: consider pyridoxine supplementation in patients at risk for peripheral neuropathy. - Pregnancy and lactation: assess risk‑benefit ratio, as safety data are limited. - Drug interactions: review concomitant medications for potential hepatic enzyme induction. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Isoniazid can alter the metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Rifampicin: reduces isoniazid plasma levels, compromising efficacy. - Phenytoin: increased metabolism leading to sub‑therapeutic isoniazid concentrations. - Carbamazepine: may enhance hepatotoxic risk.

Moderate Interactions (Monitor Closely): - Alcohol: additive hepatotoxic potential; monitor liver function. - Antiretrovirals (e.g., efavirenz): may increase neurotoxicity; observe for CNS symptoms. - Warfarin: possible increase in INR; check coagulation parameters regularly.